Editorial: Pathogenesis, treatment, and future directions for rare T-cell leukemias

• Marco Herling,
• Marco Herling,
• Wael Jarjour,
• Anjali Mishra,
• Jonathan E. Brammer

Affiliations

Marco Herling

Department of Hematology, Cellular Therapy, and Hemostasis University of Leipzig, Leipzig, Germany

Marco Herling

Department of Internal Medicine, Center for Integrated Oncology (CIO-ABCD), Aachen-Bonn-Cologne-Duesseldorf, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne (UoC), Cologne, Germany

Wael Jarjour

Division of Rheumatology, The Ohio State University, Columbus, OH, United States

Anjali Mishra

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology and Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States

Jonathan E. Brammer

Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States